Publication: Mitral Regurgitation in Low-Flow, Low-Gradient Aortic Stenosis Patients Undergoing TAVR: Insights From the TOPAS-TAVI Registry.
dc.contributor.author | Freitas-Ferraz, Afonso B | |
dc.contributor.author | Lerakis, Stamatios | |
dc.contributor.author | Barbosa Ribeiro, Henrique | |
dc.contributor.author | Gilard, Martine | |
dc.contributor.author | Cavalcante, João L | |
dc.contributor.author | Makkar, Raj | |
dc.contributor.author | Herrmann, Howard C | |
dc.contributor.author | Windecker, Stephan | |
dc.contributor.author | Enriquez-Sarano, Maurice | |
dc.contributor.author | Cheema, Asim N | |
dc.contributor.author | Nombela-Franco, Luis | |
dc.contributor.author | Amat-Santos, Ignacio | |
dc.contributor.author | Muñoz-García, Antonio J | |
dc.contributor.author | Garcia Del Blanco, Bruno | |
dc.contributor.author | Zajarias, Alan | |
dc.contributor.author | Lisko, John C | |
dc.contributor.author | Hayek, Salim | |
dc.contributor.author | Babaliaros, Vasilis | |
dc.contributor.author | Le Ven, Florent | |
dc.contributor.author | Gleason, Thomas G | |
dc.contributor.author | Chakravarty, Tarun | |
dc.contributor.author | Szeto, Wilson Y | |
dc.contributor.author | Clavel, Marie-Annick | |
dc.contributor.author | de Agustin, Alberto | |
dc.contributor.author | Serra, Vicenç | |
dc.contributor.author | Schindler, John T | |
dc.contributor.author | Dahou, Abdellaziz | |
dc.contributor.author | Annabi, Mohamed-Salah | |
dc.contributor.author | Pelletier-Beaumont, Emilie | |
dc.contributor.author | Pibarot, Philippe | |
dc.contributor.author | Rodés-Cabau, Josep | |
dc.date.accessioned | 2023-02-08T14:41:23Z | |
dc.date.available | 2023-02-08T14:41:23Z | |
dc.date.issued | 2020-02-12 | |
dc.description.abstract | This study sought to determine the incidence, clinical impact, and changes over time of mitral regurgitation (MR) in patients with low-flow, low-gradient aortic stenosis (LFLG-AS) undergoing transcatheter aortic valve replacement (TAVR). Few data exist on the clinical impact and changes in severity over time of MR in patients with LFLG-AS undergoing TAVR. A total of 308 TAVR candidates with LFLG-AS were included. Patients were categorized according to MR severity at baseline, and presence of MR improvement at 12-month follow-up. Clinical outcomes were assessed at 1 and 12 months (+ echocardiography), and yearly thereafter. Baseline mild and moderate-to-severe MR were present in 118 (38.3%) and 115 (37.3%) patients, respectively. MR was of functional and mixed etiology in 77.2% and 22.7% of patients, respectively. A total of 131 patients (42.5%) died after a median follow-up of 2 (1 to 3) years. Baseline moderate-or-greater MR had no impact on mortality (hazard ratio [HR]: 1.34; 95% confidence interval [CI]: 0.72 to 2.48) or heart failure hospitalization (HR: 1.02; 95% CI: 0.49 to 2.10). At 1-year follow-up, MR improved in 44.3% of patients and remained unchanged/worsened in 55.7%. The lack of MR improvement was associated with a higher risk of all-cause and cardiac mortality (HR: 2.02; 95% CI: 1.29 to 3.17; HR: 3.03; 95% CI: 1.27 to 7.23, respectively), rehospitalization for cardiac causes (HR: 1.50; 95% CI: 1.04 to 2.15), and an increased overall-mortality/heart failure rehospitalization (HR: 1.94; 95% CI: 1.25 to 3.02). A higher baseline left ventricular end-diastolic diameter and a higher increase in left ventricular ejection fraction were found to be independent predictors of MR improvement at 1-year follow-up (odds ratio: 0.69; 95% CI: 0.51 to 0.94; and odds ratio: 0.81; 95% CI: 0.67 to 0.96, respectively). Most TAVR candidates with LFLG-AS had some degree of MR, of functional origin in most cases. MR improved in about one-half of patients, with larger left ventricular size and a higher increase in left ventricular ejection fraction post-TAVR determining MR improvement over time. The lack of MR improvement at 1 year was associated with poorer outcomes. | |
dc.identifier.doi | 10.1016/j.jcin.2019.11.042 | |
dc.identifier.essn | 1876-7605 | |
dc.identifier.pmid | 32061600 | |
dc.identifier.unpaywallURL | https://doi.org/10.1016/j.jcin.2019.11.042 | |
dc.identifier.uri | http://hdl.handle.net/10668/15113 | |
dc.issue.number | 5 | |
dc.journal.title | JACC. Cardiovascular interventions | |
dc.journal.titleabbreviation | JACC Cardiovasc Interv | |
dc.language.iso | en | |
dc.organization | Hospital Universitario Virgen de la Victoria | |
dc.page.number | 567-579 | |
dc.pubmedtype | Journal Article | |
dc.pubmedtype | Multicenter Study | |
dc.pubmedtype | Research Support, Non-U.S. Gov't | |
dc.rights.accessRights | open access | |
dc.subject | low-flow low-gradient aortic stenosis | |
dc.subject | mitral regurgitation | |
dc.subject | reduced left ventricular ejection fraction | |
dc.subject | transcatheter aortic valve replacement | |
dc.subject.mesh | Aged | |
dc.subject.mesh | Aged, 80 and over | |
dc.subject.mesh | Aortic Valve | |
dc.subject.mesh | Aortic Valve Stenosis | |
dc.subject.mesh | Disease Progression | |
dc.subject.mesh | Female | |
dc.subject.mesh | Heart Failure | |
dc.subject.mesh | Heart Valve Prosthesis | |
dc.subject.mesh | Hemodynamics | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Male | |
dc.subject.mesh | Mitral Valve | |
dc.subject.mesh | Mitral Valve Insufficiency | |
dc.subject.mesh | Patient Readmission | |
dc.subject.mesh | Prospective Studies | |
dc.subject.mesh | Recovery of Function | |
dc.subject.mesh | Registries | |
dc.subject.mesh | Retrospective Studies | |
dc.subject.mesh | Risk Factors | |
dc.subject.mesh | Severity of Illness Index | |
dc.subject.mesh | Time Factors | |
dc.subject.mesh | Transcatheter Aortic Valve Replacement | |
dc.subject.mesh | Treatment Outcome | |
dc.title | Mitral Regurgitation in Low-Flow, Low-Gradient Aortic Stenosis Patients Undergoing TAVR: Insights From the TOPAS-TAVI Registry. | |
dc.type | research article | |
dc.type.hasVersion | VoR | |
dc.volume.number | 13 | |
dspace.entity.type | Publication |